Clinical trial NCT01267955: Vismodegib in Treating Patients With Advanced Chondrosarcomas
Official title: A Phase 2 Study of GDC-0449 in Patients With Advanced Chondrosarcomas
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Clear Cell Chondrosarcoma
Dedifferentiated Chondrosarcoma
Locally Advanced Chondrosarcoma
Mesenchymal Chondrosarcoma
Metastatic Chondrosarcoma
Primary Central Chondrosarcoma
Unresectable Primary Central Chondrosarcoma
Lead sponsor: National Cancer Institute (NCI)
Sponsor class: NIH
First posted: 2010-12-29
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This phase II trial studies how well vismodegib works in treating patients with chondrosarcomas that have spread to other places in the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as vismodegib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Detailed description: PRIMARY OBJECTIVES:

I. To evaluate the antitumor activity of GDC-0449 (vismodegib) in terms of 6-month clinical benefit rate (complete response, partial response, and stable disease, as per the revised Response Evaluation Criteria in Solid Tumors \[RECIST\] criteria 2009).

SECONDARY OBJECTIVES:

I. Best overall response (as per the revised RECIST criteria 2009). II. 1- and 2-year progression-free survival. III. 1- and 2-year overall survival. IV. GDC-0449 safety. V. Pharmacogenomics analysis of predictive markers of treatment outcome.

OUTLINE:

Patients receive vismodegib orally (PO) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed up every 3 months.

Eligibility criteria: Inclusion Criteria:

* Patients must have histologically confirmed diagnosis of chondrosarcoma (conventional, mesenchymal, dedifferentiated or clear cell subtypes)
* Patients must have measurable disease (outside any previously irradiated field) defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 10 mm with spiral computed tomography (CT) scan
* No more than three prior lines of chemotherapy for advanced disease (including no more than 450 mg/m\^2 doxorubicin); at least three weeks since last chemotherapy (six weeks in case of nitrosoureas and mitomycin C), immunotherapy or any other pharmacological treatment and/or radiotherapy
* Life expectancy of greater than 3 months
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%)
* Leukocytes \>= 3,000/mcL
* Absolute neutrophil count \>= 1,500/mcL
* Platelets \>= 100,000/mcL
* Total bilirubin within normal institutional limits
* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 X institutional upper limit of normal
* Creatinine within normal institutional limits OR creatinine clearance \> 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal
* Metastatic or unresectable locally advanced disease
* Documented disease progression (as per RECIST) before study entry
* Women of child-bearing potential and men must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to study entry, for the duration of study participation, and for at least 24 months post-treatment for female patients and for 2 months for male patients; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
* Women of childbearing potential are required to have a negative serum pregnancy test (with a sensitivity of at least 25 mIU/mL) within 7 days prior to initiation of GDC-0449 (serum or urine); a pregnancy test (serum or urine) will be administered every 4 weeks while on study within the 24-hour period prior to the administration of GDC-0449; a positive urine test must be confirmed by a serum pregnancy test; prior to dispensing GDC-0449, the investigator must confirm and document the patient's use of two contraceptive methods, dates of negative pregnancy test, and confirm the patient's understanding of the teratogenic potential of GDC-0449

  * Women of childbearing potential are defined as follows:

    * Patients with regular menses
    * Patients with amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding
    * Women who have had a tubal ligation
  * Women are considered not to be of childbearing potential for the following reasons:

    * The patient has undergone hysterectomy and/or bilateral oophorectomy
    * The patient is post-menopausal defined by amenorrhea for at least 1 year in a woman \> 50 years old
    * The patient has permanent premature ovarian failure confirmed by specialist gynecologist
* Ability to understand and the willingness to sign a written informed consent document
* In accordance with French Regulatory Authorities: Patients with French Social Security in compliance with the French law relating to biomedical research (Huriet Law 88-1138 and related decrees)

Exclusion Criteria:

* Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier
* Patients may not be receiving any other investigational agents
* Patients with known brain metastases should be excluded from this clinical trial
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to GDC-0449 or other agents used in the study
* Patients with malabsorption syndrome or other condition that would interfere with intestinal absorption; patients must be able to swallow capsules
* Patients with clinically important history of liver disease, including viral or other hepatitis, or cirrhosis are ineligible
* Patients with uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, or hypokalemia defined as less than the lower limit of normal for the institution, despite adequate electrolyte supplementation, are excluded from this study
* Tumor tissue sample not available for pathological review and/or correlative studies
* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GDC-0449; these potential risks may also apply to other agents used in this study
* Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Primary outcomes:
measure: Clinical Benefit Rate (CBR) Based on Centralized Imaging Review as Per RECIST 1.1
timeFrame: At 6 months after inclusion
Secondary outcomes:
measure: Progression-free Survival
timeFrame: Time from start of treatment to time of progression or death, whichever occurs first, assessed up to 3 years
measure: Overall Survival Per Response Evaluation Criteria in Solid Tumors Criteria 2009
timeFrame: Time from start of treatment to the time of death, assessed up to 3 years
measure: Duration of Response
timeFrame: From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
measure: Mutational Status of Patched 1 and Smoothened
timeFrame: Baseline
measure: Expression Pattern of Hedgehog Signaling Molecules by Using Quantitative Reverse Transcription-polymerase Chain Reaction and Immunohistochemistry
timeFrame: Baseline
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: Institut Bergonie Cancer Center
city: Lille
country: France
facility: Centre Oscar Lambert
city: Lyon
country: France
facility: Centre Leon Berard
city: Marseille
country: France
facility: Hopital De La Timone
city: Paris
country: France
facility: Institut Curie Paris
city: Villejuif
country: France
facility: Gustave Roussy
Study officials:
affiliation: Institut Bergonie Cancer Center
name: Antoine Italiano
role: PRINCIPAL_INVESTIGATOR
References:
citation: Italiano A, Le Cesne A, Bellera C, Piperno-Neumann S, Duffaud F, Penel N, Cassier P, Domont J, Takebe N, Kind M, Coindre JM, Blay JY, Bui B. GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. Ann Oncol. 2013 Nov;24(11):2922-6. doi: 10.1093/annonc/mdt391.